Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 16/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.66 |
| ▸ | CDK1 | P06493 | 7/20 | 0.59 |
| ▸ | CDK4 | P11802 | 1/20 | 0.50 |
| ▸ | CDKL1 | Q00532 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4247639 | 0.88 | CDK2 (0.49) | CDK2KCNH2CDK1 | |
| SCHEMBL12861917 | 0.86 | CDK2 (0.60) | CDK2KCNH2CDK1 | |
| Hydrochloric Acid SCHEMBL1155863 | 0.86 | CDK2 (0.60) | CDK2KCNH2CDK1 | |
| SCHEMBL4243729 | 0.83 | CDK2 (0.66) | CDK2KCNH2CDK1 | |
| SCHEMBL3937054 | 0.82 | CDK2 (0.79) | CDK2KCNH2CDK1 | |
| SCHEMBL5234131 | 0.82 | CDK2 (0.72) | CDK2KCNH2CDK1 | |
| Hydrochloric Acid SCHEMBL1156127 | 0.81 | CDK2 (0.77) | CDK2KCNH2CDK1 | |
| SCHEMBL27382932 | 0.81 | CDK2 (0.83) | CDK2KCNH2CDK1 | |
| SCHEMBL30828143 | 0.81 | CDK2 (0.83) | CDK2KCNH2CDK1 | |
| SCHEMBL30828131 | 0.80 | CDK2 (0.76) | CDK2KCNH2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028489-A1 | Pyrimidine Derivatives and Their Use for Treating Bone-Related Disorders | ANDERSSON LARS | 2011-02-03 | — | — | US | claimed |
| US-20080214560-A1 | Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | claimed |
| EP-1942897-A1 | USE OF PYRIMIDINE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR PREVENTION AND/OR TREATMENT OF ALZHEIMER'S DISEASE | AstraZeneca AB (SE) | 2008-07-16 | — | — | EP | claimed |
| WO-2007040436-A1 | USE OF PYRIMIDINE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR PREVENTION AND/OR TREATMENT OF ALZHEIMER’S DISEASE | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | claimed |
| US-20110028489-A1 | Pyrimidine Derivatives and Their Use for Treating Bone-Related Disorders | ANDERSSON LARS | 2011-02-03 | — | — | US | disclosed |
| US-20110028489-A1 | Pyrimidine Derivatives and Their Use for Treating Bone-Related Disorders | ANDERSSON LARS | 2011-02-03 | — | — | US | disclosed |
| US-20110028489-A1 | Pyrimidine Derivatives and Their Use for Treating Bone-Related Disorders | ANDERSSON LARS | 2011-02-03 | — | — | US | disclosed |
| US-20080214560-A1 | Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| US-20080214560-A1 | Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| US-20080214560-A1 | Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| EP-1942897-A1 | USE OF PYRIMIDINE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR PREVENTION AND/OR TREATMENT OF ALZHEIMER'S DISEASE | AstraZeneca AB (SE) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007040436-A1 | USE OF PYRIMIDINE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR PREVENTION AND/OR TREATMENT OF ALZHEIMER’S DISEASE | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007040436-A1 | USE OF PYRIMIDINE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR PREVENTION AND/OR TREATMENT OF ALZHEIMER’S DISEASE | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214560-A1 | Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease | TYMS, TYMP, ADORA1 | CDK2 357/4885KCNH2 4221/4885CDK1 406/4885 |
| US-20110028489-A1 | Pyrimidine Derivatives and Their Use for Treating Bone-Related Disorders | TYMP, DPYD, HPRT1 | CDK2 339/4885KCNH2 4545/4885CDK1 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.